The macrolide-lincosamide-streptogramin B resistance phenotypes characterized by using a specifically deleted, antibiotic-sensitive strain of Streptomyces lividans.
Genes conferring resistance to macrolide, lincosamide, and streptogramin B (MLS) antibiotics via ribosomal modification are widespread in bacteria, including clinical isolates and MLS-producing actinomycetes. Such erm-type genes encode enzymes that mono- or dimethylate residue A-2058 of 23S rRNA. The different phenotypes resulting from monomethylation (MLS-I phenotype, conferred by erm type I genes) or dimethylation (MLS-II phenotype due to erm type II genes) have been characterized by introducing tlrD or ermE, respectively, into an MLS-sensitive derivative of Streptomyces lividans TK21. This strain (designated OS456) was generated by specific replacement of the endogenous resistance genes lrm and mgt. The MLS-I phenotype is characterized by high-level resistance to lincomycin with only marginal resistance to macrolides such as chalcomycin or tylosin, whereas the MLS-II phenotype involves high-level resistance to all MLS drugs. Mono- and dimethylated ribosomes were introduced into a cell-free protein-synthesizing system prepared from S. lividans and compared with unmodified particles in their response to antibiotics. There was no simple correlation between the relative potencies of MLS drugs at the level of the target site (i.e., the ribosome) and their antibacterial activities expressed as MICs.
Pernodet
J L
JL
Laboratoire de Biologie et Génétique Moléculaire, Université Paris-Sud XI, Orsay, France.
Fish
S
S
Blondelet-Rouault
M H
MH
Cundliffe
E
E
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000096:biosynthesis; D002474:Cell-Free System; D004352:Drug Resistance, Microbial / Q000235:genetics; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D005798:Genes, Bacterial; D055231:Lincosamides; D018942:Macrolides / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010641:Phenotype; D010957:Plasmids; D012329:RNA, Bacterial / Q000032:analysis / Q000378:metabolism; D012270:Ribosomes / Q000187:drug effects / Q000378:metabolism; D013302:Streptomyces / Q000187:drug effects* / Q000235:genetics* / Q000378:metabolism; D014769:Virginiamycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D055231:Lincosamides; D018942:Macrolides; D012329:RNA, Bacterial; D014769:Virginiamycin